Global Chemotherapy-induced Thrombocytopenia Therapeutics Market, By Drug Class (Thrombopoietin Receptor Agonists, Thrombopoietic Agents, and Others), By Route of Administration (Oral and Injectable), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be valued at US$ 1,531.3 Mn in 2023, and is expected to exhibit a CAGR of 5% during the forecast period (2023-2030), as highlighted in a new report published by Coherent Market Insights.
Market players are engaged in getting product approvals by regulatory authorities, and this is expected to drive the global chemotherapy-induced thrombocytopenia therapeutics market growth. For instance, in February 2021, G1 Therapeutics, Inc., a commercial-stage oncology company, announced that the U.S. Food and Drug Administration (FDA) has approved COSELA (trilaciclib) for injection to reduce the incidence of chemotherapy-induced myelosuppression in adult patients when given before a platinum/etoposide-containing regimen or topotecan-containing regimen for advanced-stage small cell lung cancer (ES-SCLC). Myelosuppression, or chemotherapy-induced bone marrow loss, can raise the risk of infection, anemia, thrombocytopenia, and other consequences. As a result, following further studies, this approved medicine may be used to treat chemotherapy-induced thrombocytopenia.
Global Chemotherapy-induced Thrombocytopenia Therapeutics Market - Impact of Coronavirus (COVID-19) Pandemic
The World Health Organization (WHO) designated the illness caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which first appeared in Wuhan (province of Hubei, China), in the last months of 2019, as "coronavirus disease 2019" or COVID-19. This virus spread quickly, and had a serious negative impact on the economies, social behaviors, and healthcare of every country in the world.
COVID-19 affected the economy in three main ways: by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to the lockdown, several countries, such as India, China, Brazil, and others, faced problems regarding the transportation of raw materials and manufacturing supplies from one place to another.
Moreover, COVID-19 had a negative impact on the global chemotherapy-induced thrombocytopenia therapeutics market. The COVID-19 pandemic impacted virtually every aspect of cancer care and research from new risks for cancer patients to disrupting the delivery of cancer treatment and the continuity of cancer research. For instance, in June 2020, a study was published in the Current Oncology, a Canada-based cancer research journal, which assessed the impact of COVID-19 outbreak on Stage II and Stage III colon cancer patients who were taking adjuvant chemotherapy treatment in China in which the patients had to delay or modify their chemotherapy regimen during the COVID-19 outbreak.
Global Chemotherapy-induced Thrombocytopenia Therapeutics Market: Key Developments
For instance, in September 2020, Mylan N.V., a global pharmaceutical company with a pipeline of chemotherapy-induced thrombocytopenia therapeutics, announced an agreement to acquire the related intellectual property and commercialization rights of Aspen Pharmacare Holdings Limited, a publicly traded multinational pharmaceutical company with a thrombosis business in Europe, for US$ 683.2 million, subject to customary closing conditions and European regulatory approvals. The transaction is projected to be immediately accretive to Mylan and VIATRISTM following the completion of Mylan's previously announced combination with Upjohn, which concluded in the fourth quarter of 2020.
Browse 26 Market Data Tables and 29 Figures spread through 180 Pages and in-depth TOC on “Global Chemotherapy-induced Thrombocytopenia Therapeutics Market”- Forecast to 2030, Global Chemotherapy-induced Thrombocytopenia Therapeutics Market, By Drug Class (Thrombopoietin Receptor Agonists, Thrombopoietic Agents, and Others), By Route of Administration (Oral and Injectable), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)
To know the latest trends and insights prevalent in this market, click the link below:
Key Takeaways of the Global Chemotherapy Induced Thrombocytopenia Therapeutics Market:
- The global Chemotherapy Induced Thrombocytopenia Therapeutics Market is expected to exhibit a CAGR of 5% during the forecast period. The merger with emerging economies offers lucrative growth opportunities for players in the global Chemotherapy Induced Thrombocytopenia Therapeutics Market.
- Among route of administration, the injectable segment is expected to hold a dominant position in the global Chemotherapy Induced Thrombocytopenia Therapeutics Market during the forecast period due to a robust pipeline of injectable to treat chemotherapy-induced thrombocytopenia. For instance, according to clinicaltrial.gov, in September 2022, QL-0911 was in Phase 3 development for the treatment of chronic primary immune thrombocytopenia and chemotherapy-associated thrombocytopenia by Qilu Pharmaceutical, a pharmaceutical company. This drug candidate is delivered subcutaneously. QL-0911 is a peptidomimetic of recombinant human platelet-Fc fusion protein.
- Among region, North America is expected to be the dominant region in the global Chemotherapy Induced Thrombocytopenia Therapeutics Market owing to increasing cancer cases in the region. For instance, according to the Cancer Treatment & Survivorship Facts & Figures 2019-2021 Report published by the American Cancer Society, Inc., the estimated number of cancer cases in the U.S. was around 16,920,370, as of January 1, 2019.
- The major players operating in the global Chemotherapy Induced Thrombocytopenia Therapeutics Market are Amgen, Inc., Novartis AG, Pfizer Inc., Swedish Orphan Biovitrum AB, Jiangsu HengRui Medicine Co., Ltd., Teva Pharmaceutical Industries Ltd., and Mylan N.V.
